ATOS
|Atossa Genetics Inc
NASDAQ
USD 0.86
+0.00|+0.32%
Current Price
USD 0.86
Change
+USD 0.00 (0.32%)
P/E Ratio
Dividend Yield
Market Cap
100.38M
Volume
681,502
Open
USD 0.89
Previous Close
USD 0.86
52-Week High
USD 1.66
52-Week Low
USD 0.55
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa ...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Steven C. Quay FCAP, M.D., Ph.D.
Employees:15
Headquarters:Seattle, USA
Website:www.atossatherapeutics.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions